Showing results (201-210 of 299) with videos related to

Sort By:
Pageof 30
Journal of Korean Medical Science|January 1, 2019
Clinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung CancerYoung Ju Jung, In-Jae Oh, Youndong Kim, et al.
Molecular Cancer Therapeutics|December 17, 2010
Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutationJin Kyung Rho, Yun Jung Choi, Byung-Suk Jeon, et al.
Oncotarget|September 24, 2017
Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangementSe Hoon Choi, Dong Ha Kim, Yun Jung Choi, et al.
Lung Cancer (Amsterdam, Netherlands)|April 30, 2025
Clinical effect of pulmonary rehabilitation during radiotherapy in lung cancer: A randomized controlled trialJang Ho Lee, Seungwoo Cha, Eun Jae Ko, et al.
Journal of Korean Medical Science|December 8, 2017
Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case ReportCheol Kyu Park, Jae Young Hur, Chang Min Choi, et al.
Targeted Oncology|April 15, 2020
Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung CancerYong-Hee Cho, Myeong Geun Choi, Dong Ha Kim, et al.
Plos One|December 9, 2014
Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790MKwang Sup So, Cheol Hyeon Kim, Jin Kyung Rho, et al.
International Journal of Clinical and Experimental Pathology|November 18, 2014
Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancerHo-Cheol Kim, Joon Seon Song, Jae Cheol Lee, et al.
Oncoimmunology|September 14, 2020
Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitorsSang Eun Won, Hyo Jung Park, Sangil Byun, et al.
Journal of Clinical Medicine|January 21, 2022
CDCP1 Expression Is a Potential Biomarker of Poor Prognosis in Resected Stage I Non-Small-Cell Lung CancerYunha Nam, Chang-Min Choi, Young Soo Park, et al.
Pageof 30